Broad neutralization of SARS-related viruses by human monoclonal antibodies

Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Wec, Anna Z., Wrapp, Daniel, Herbert, Andrew S., Maurer, Daniel P., Haslwanter, Denise, Sakharkar, Mrunal, Jangra, Rohit K., Dieterle, M. Eugenia, Lilov, Asparouh, Huang, Deli, Tse, Longping V., Johnson, Nicole V., Hsieh, Ching-Lin, Wang, Nianshuang, Nett, Juergen H., Champney, Elizabeth, Burnina, Irina, Brown, Michael, Lin, Shu, Sinclair, Melanie, Johnson, Carl, Pudi, Sarat, Bortz, Robert, Wirchnianski, Ariel S., Laudermilch, Ethan, Florez, Catalina, Fels, J. Maximilian, O’Brien, Cecilia M., Graham, Barney S., Nemazee, David, Burton, Dennis R., Baric, Ralph S., Voss, James E., Chandran, Kartik, Dye, John M., McLellan, Jason S., Walker, Laura M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299279/
https://www.ncbi.nlm.nih.gov/pubmed/32540900
http://dx.doi.org/10.1126/science.abc7424
Descripción
Sumario:Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified 200 SARS coronavirus 2 (SARS-CoV-2) binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of preexisting memory B cells elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines.

Ejemplares similares